Research ExplorerPublicationsThe Natural History of Renal-Cell Carcinoma with Sarcomatoid...

The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis

Standard

The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. / Tully, Karl H; Berg, Sebastian; Paciotti, Marco; Janisch, Florian; Reese, Stephen W; Noldus, Joachim; Shariat, Shahrokh F; Choueiri, Toni; Müller, Guido; McGregor, Bradley; Chang, Steven L; Trinh, Quoc-Dien; Mossanen, Matthew.

In: CLIN GENITOURIN CANC, Vol. 21, No. 1, 02.2023, p. 63-68.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tully, KH, Berg, S, Paciotti, M, Janisch, F, Reese, SW, Noldus, J, Shariat, SF, Choueiri, T, Müller, G, McGregor, B, Chang, SL, Trinh, Q-D & Mossanen, M 2023, 'The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis', CLIN GENITOURIN CANC, vol. 21, no. 1, pp. 63-68. https://doi.org/10.1016/j.clgc.2022.11.015

APA

Tully, K. H., Berg, S., Paciotti, M., Janisch, F., Reese, S. W., Noldus, J., Shariat, S. F., Choueiri, T., Müller, G., McGregor, B., Chang, S. L., Trinh, Q-D., & Mossanen, M. (2023). The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. CLIN GENITOURIN CANC, 21(1), 63-68. https://doi.org/10.1016/j.clgc.2022.11.015

Vancouver

Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J et al. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. CLIN GENITOURIN CANC. 2023 Feb;21(1):63-68. https://doi.org/10.1016/j.clgc.2022.11.015

Bibtex

@article{b0e52bd1f39f4502b66b11d410ccc7bd,
title = "The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis",
abstract = "BACKGROUND: Sarcomatoid differentiation in patients diagnosed with renal cell carcinoma (sRCC) imply aggressive behavior and often metastatic disease at the time of diagnosis. We aim to examine the overall survival (OS) in patients with sRCC using the National Cancer Database (NCDB).MATERIALS AND METHODS: We identified patients diagnosed with sRCC between 2010-2015. We employed Kaplan-Meier curves and multivariable Cox proportional hazards regression models to examine the impact of several potential risk factors on OS in patients diagnosed with sRCC.RESULTS: In total, 8582 patients with renal cancer were found to have sarcomatoid differentiation, with 4105 patients (47.8%) being diagnosed with AJCC stage IV disease. The median OS was 17.2 months (IQR 5.4, 68.7 months). Compared to patients who did not undergo surgery, OS was significantly longer in patients undergoing partial or total nephrectomy across all stages. This result remained consistent on multivariable Cox proportional hazards regression adjusting for patient and tumor characteristics (Surgery: Hazard ratio 0.54, 95%Confidence interval 0.43 - 0.68, P < .001).CONCLUSION: In our cohort sRCC was found to have an unfavorable median OS, which was mainly caused by the high number of cases diagnosed with late-stage disease. Additionally, surgery was associated with favorable OS across all stages. This study supports the notion that surgical therapy, even in the setting of cytoreductive surgery, provides a survival benefit in patients with sRCC.",
keywords = "Humans, Carcinoma, Renal Cell/pathology, Prognosis, Retrospective Studies, Kidney Neoplasms/pathology, Nephrectomy, Cell Differentiation",
author = "Tully, {Karl H} and Sebastian Berg and Marco Paciotti and Florian Janisch and Reese, {Stephen W} and Joachim Noldus and Shariat, {Shahrokh F} and Toni Choueiri and Guido M{\"u}ller and Bradley McGregor and Chang, {Steven L} and Quoc-Dien Trinh and Matthew Mossanen",
note = "Copyright {\textcopyright} 2022. Published by Elsevier Inc.",
year = "2023",
month = feb,
doi = "10.1016/j.clgc.2022.11.015",
language = "English",
volume = "21",
pages = "63--68",
journal = "CLIN GENITOURIN CANC",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis

AU - Tully, Karl H

AU - Berg, Sebastian

AU - Paciotti, Marco

AU - Janisch, Florian

AU - Reese, Stephen W

AU - Noldus, Joachim

AU - Shariat, Shahrokh F

AU - Choueiri, Toni

AU - Müller, Guido

AU - McGregor, Bradley

AU - Chang, Steven L

AU - Trinh, Quoc-Dien

AU - Mossanen, Matthew

N1 - Copyright © 2022. Published by Elsevier Inc.

PY - 2023/2

Y1 - 2023/2

N2 - BACKGROUND: Sarcomatoid differentiation in patients diagnosed with renal cell carcinoma (sRCC) imply aggressive behavior and often metastatic disease at the time of diagnosis. We aim to examine the overall survival (OS) in patients with sRCC using the National Cancer Database (NCDB).MATERIALS AND METHODS: We identified patients diagnosed with sRCC between 2010-2015. We employed Kaplan-Meier curves and multivariable Cox proportional hazards regression models to examine the impact of several potential risk factors on OS in patients diagnosed with sRCC.RESULTS: In total, 8582 patients with renal cancer were found to have sarcomatoid differentiation, with 4105 patients (47.8%) being diagnosed with AJCC stage IV disease. The median OS was 17.2 months (IQR 5.4, 68.7 months). Compared to patients who did not undergo surgery, OS was significantly longer in patients undergoing partial or total nephrectomy across all stages. This result remained consistent on multivariable Cox proportional hazards regression adjusting for patient and tumor characteristics (Surgery: Hazard ratio 0.54, 95%Confidence interval 0.43 - 0.68, P < .001).CONCLUSION: In our cohort sRCC was found to have an unfavorable median OS, which was mainly caused by the high number of cases diagnosed with late-stage disease. Additionally, surgery was associated with favorable OS across all stages. This study supports the notion that surgical therapy, even in the setting of cytoreductive surgery, provides a survival benefit in patients with sRCC.

AB - BACKGROUND: Sarcomatoid differentiation in patients diagnosed with renal cell carcinoma (sRCC) imply aggressive behavior and often metastatic disease at the time of diagnosis. We aim to examine the overall survival (OS) in patients with sRCC using the National Cancer Database (NCDB).MATERIALS AND METHODS: We identified patients diagnosed with sRCC between 2010-2015. We employed Kaplan-Meier curves and multivariable Cox proportional hazards regression models to examine the impact of several potential risk factors on OS in patients diagnosed with sRCC.RESULTS: In total, 8582 patients with renal cancer were found to have sarcomatoid differentiation, with 4105 patients (47.8%) being diagnosed with AJCC stage IV disease. The median OS was 17.2 months (IQR 5.4, 68.7 months). Compared to patients who did not undergo surgery, OS was significantly longer in patients undergoing partial or total nephrectomy across all stages. This result remained consistent on multivariable Cox proportional hazards regression adjusting for patient and tumor characteristics (Surgery: Hazard ratio 0.54, 95%Confidence interval 0.43 - 0.68, P < .001).CONCLUSION: In our cohort sRCC was found to have an unfavorable median OS, which was mainly caused by the high number of cases diagnosed with late-stage disease. Additionally, surgery was associated with favorable OS across all stages. This study supports the notion that surgical therapy, even in the setting of cytoreductive surgery, provides a survival benefit in patients with sRCC.

KW - Humans

KW - Carcinoma, Renal Cell/pathology

KW - Prognosis

KW - Retrospective Studies

KW - Kidney Neoplasms/pathology

KW - Nephrectomy

KW - Cell Differentiation

U2 - 10.1016/j.clgc.2022.11.015

DO - 10.1016/j.clgc.2022.11.015

M3 - SCORING: Journal article

C2 - 36517393

VL - 21

SP - 63

EP - 68

JO - CLIN GENITOURIN CANC

JF - CLIN GENITOURIN CANC

SN - 1558-7673

IS - 1

ER -